Suvi Sorsa
About
Suvi Sorsa is a scholar working on Oncology, Genetics and Molecular Biology.
According to data from OpenAlex, Suvi Sorsa has authored 22 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Suvi Sorsa's work include CAR-T cell therapy research (22 papers), Virus-based gene therapy research (20 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Suvi Sorsa is often cited by papers focused on CAR-T cell therapy research (22 papers), Virus-based gene therapy research (20 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Suvi Sorsa collaborates with scholars based in Finland, Denmark and United States. Suvi Sorsa's co-authors include Riikka Havunen, Akseli Hemminki, Mikko Siurala, João M. Santos, Siri Tähtinen, Anna Kanerva, Víctor Cervera-Carrascón, Marjukka Anttila, Sònia Guedan and Marco Ruella and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.
In The Last Decade
Suvi Sorsa
21 papers receiving 715 citations
Peers
Suvi Sorsa
Mikko Siurala Finland
Megha Shettigar United States
Riikka Havunen Finland
Shyambabu Chaurasiya United States
Minna Oksanen Finland
Cristian Capasso Finland
Mari Hirvinen Finland
Timo Joensuu Finland
Roshni Ravindranathan United States
Arnold Kloos Germany
Citations per year, relative to Suvi Sorsa Suvi Sorsa (= 1×)
peers
Mikko Siurala
Countries citing papers authored by Suvi Sorsa
Since
Specialization
Citations
This map shows the geographic impact of Suvi Sorsa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suvi Sorsa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suvi Sorsa more than expected).
Fields of papers citing papers by Suvi Sorsa
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Suvi Sorsa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suvi Sorsa. The network helps show where Suvi Sorsa may publish in the future.
Co-authorship network of co-authors of Suvi Sorsa
This figure shows the co-authorship network connecting the top 25 collaborators of Suvi Sorsa. A scholar is included among the top collaborators of Suvi Sorsa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suvi Sorsa. Suvi Sorsa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Peltola, Katriina, Tuomo Alanko, Teijo Pellinen, et al.. (2025). Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. Journal for ImmunoTherapy of Cancer. 13(1). e010493–e010493.
2.
Bychkov, Dmitrii, Dafne C.A. Quixabeira, Tuomo Alanko, et al.. (2025). Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes. Cancer Gene Therapy. 32(6). 649–661.
3.
Santos, João M., Matthew S. Block, Johanna Mäenpää, et al.. (2024). PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5562–5562.
4.
Dréno, Brigitte, Víctor Cervera-Carrascón, Eva Ellebæk, et al.. (2023). 48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial. Immuno-Oncology Technology. 20. 100521–100521.
5.
Santos, João M., Katriina Peltola, Tuomo Alanko, et al.. (2023). 1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO). SHILAP Revista de lepidopterología. A1743–A1743.
6.
Santos, João M., Dafne C.A. Quixabeira, Susanna Grönberg-Vähä-Koskela, et al.. (2022). Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors. Molecular Therapy — Oncolytics. 28. 59–73.
7.
Heiniö, Camilla, Víctor Cervera-Carrascón, João M. Santos, et al.. (2022). Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. Frontiers in Immunology. 13. 794251–794251.
8.
Svane, Inge Marie, João M. Santos, Víctor Cervera-Carrascón, et al.. (2021). 1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes. Annals of Oncology. 32. S864–S864.
9.
Cervera-Carrascón, Víctor, Dafne C.A. Quixabeira, João M. Santos, et al.. (2021). Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. Frontiers in Immunology. 12. 706517–706517.
10.
Zafar, Sadia, Dafne C.A. Quixabeira, Víctor Cervera-Carrascón, et al.. (2020). Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes. Cancer Gene Therapy. 28(5). 442–454.
11.
Cervera-Carrascón, Víctor, Dafne C.A. Quixabeira, Riikka Havunen, et al.. (2020). Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Molecular Therapy — Oncolytics. 17. 47–60.
12.
Cervera-Carrascón, Víctor, Dafne C.A. Quixabeira, João M. Santos, et al.. (2020). Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. OncoImmunology. 9(1). 1761229–1761229.
13.
Heiniö, Camilla, Suvi Sorsa, Mikko Siurala, et al.. (2019). Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs. Human Gene Therapy. 30(6). 740–752.
14.
Cervera-Carrascón, Víctor, Mikko Siurala, João M. Santos, et al.. (2018). TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. OncoImmunology. 7(5). e1412902–e1412902.
15.
Watanabe, Keisuke, Yanping Luo, Tong Da, et al.. (2018). Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 3(7).
16.
Havunen, Riikka, João M. Santos, Suvi Sorsa, et al.. (2018). Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. Molecular Therapy — Oncolytics. 11. 109–121.
17.
Santos, João M., Víctor Cervera-Carrascón, Riikka Havunen, et al.. (2018). Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. Molecular Therapy. 26(9). 2243–2254.
18.
Zafar, Sadia, Suvi Sorsa, Mikko Siurala, et al.. (2018). CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. OncoImmunology. 7(10). e1490856–e1490856.
19.
Havunen, Riikka, Mikko Siurala, Suvi Sorsa, et al.. (2017). Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. Molecular Therapy — Oncolytics. 4. 77–86.
20.
Santos, João M., Riikka Havunen, Mikko Siurala, et al.. (2017). Adenoviral production of interleukin‐2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. International Journal of Cancer. 141(7). 1458–1468.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mikko Siurala Breakdown of academic impact, for papers by Megha Shettigar Breakdown of academic impact, for papers by Riikka Havunen Breakdown of academic impact, for papers by Shyambabu Chaurasiya Breakdown of academic impact, for papers by Minna Oksanen Breakdown of academic impact, for papers by Cristian Capasso Breakdown of academic impact, for papers by Mari Hirvinen Breakdown of academic impact, for papers by Timo Joensuu Breakdown of academic impact, for papers by Roshni Ravindranathan Breakdown of academic impact, for papers by Arnold Kloos